In vitro activity of Ro 13-9904, a new beta-lactamase-stable cephalosporin.

Content Provider	Semantic Scholar
Author	Verbist, Ludo Verhaegen, Jan L.
Copyright Year	1981
Abstract	The minimal inhibitory concentration (MIC) of Ro 13-9904 against 245 clinical isolates was determined by an agar dilution method. The activity of Ro 13-9904 against most Enterobacteriaceae was similar to that of cefotaxime; it was slightly more active than cefotaxime against Proteus mirabilis, Providencia species, and Serratia marcescens, but slightly less active against Klebsiella species. Ro 13-9904 was twofold more active than cefotaxime and threefold more active than ticarcillin against ticarcillin-susceptible Pseudomonas aeruginosa, with a mean MIC of 7.2 micrograms/ml; isolates highly resistant to ticarcillin were inhibited by a mean MIC of 17.2 micrograms/ml. Ro 13-9904 was fourfold more active than ampicillin against susceptible Haemophilus influenzae and was equally active against beta-lactamase-producing isolates. Ro 13-9904 was highly active against pneumococci and moderately active (MIC, 4 micrograms/ml) against Staphylococcus aureus isolates, whether they were susceptible or resistant to penicillin G. Oxacillin-resistant S. aureus and Streptococcus faecalis were completely resistant to Ro 13-9904 (MIC, greater than 128 micrograms/ml).
Starting Page	247
Ending Page	249
Page Count	3
File Format	PDF HTM / HTML
Alternate Webpage(s)	http://aac.asm.org/content/19/2/222.full.pdf
PubMed reference number	6289726v1
Volume Number	19
Issue Number	2
Journal	Antimicrobial agents and chemotherapy
Language	English
Access Restriction	Open
Subject Keyword	Agar Ampicillin Cefotaxime Cephalosporins Chancroids Enterococcus faecalis Influenza Moderate Response Oxacillin Penicillins Proteus mirabilis Serratia marcescens Staphylococcus aureus Ticarcillin beta-Lactamase
Content Type	Text
Resource Type	Article